Clinical trials: Cervical Disease
- Condition Cervical Disease
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Uterine Cervical Incompetence
Dilapan-S Osmotic Dilator in Pre-induction of Labor
Non-interventional prospective data collection designed to evaluate clinical outcome on the efficacy of the use of Dilapan-S in the indication of labor pre-induction in women with/without a history of Caesarean section.
- Trial name
- NCT02098382
- Testing
- Dilapan-S
- Where
- Czechia
- Volunteers
- 125 people
- Sponsor
- Medicem International CR s.r.o.
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected…
- Trial name
- NCT01031069
- Testing
- GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
- Where
- 15 sites in Brazil, Estonia and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV, Cervical Cancer
Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
This dose-ranging study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate that the vaccine is well-tolerated in women (2) To evaluate immune responses in women who are between 16 and 23…
- Conditions
- HPV, Cervical Cancer, Premalignancy Anogenital Warts
- Trial name
- NCT00260039
- Testing
- Comparator: Gardasil, Comparator: octavalent HPV Vaccine - dose formulation 1, Comparator: octavalent HPV Vaccine - dose formulation 2
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women
The purpose of this phase IIB MedImmune-sponsored study was to evaluate the efficacy of the HPV-16/18 VLP vaccine in the prevention of infection with HPV-16 and/or HPV-18 in adolescent and young adult women.
- Trial name
- NCT00689741
- Testing
- Cervarix
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Spinal Stenosis Occipito-Atlanto-Axial, Spinal Disease
Streamline Occipito-Cervico-Thoracic System Post-Market Clinical Follow-up
This is a multi-center, post-market, retrospective study design to collect safety and performance data for patients implanted with the Streamline OCT System.
- Conditions
- Spinal Stenosis Occipito-Atlanto-Axial, Spinal Disease, Spinal Stenosis Cervical, Spinal Stenosis Cervicothoracic Region
- Trial name
- OCT PMCF (NCT04171544)
- Testing
- Streamline Occipito-Cervico-Thoracic Spinal Fixation System
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- RTI Surgical
Trichomonas Vaginalis
Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing
The objective of this study is to obtain female first-catch urine, vaginal swab, endocervical swab, and cervical specimens collected in PreservCyt Solution ("PreservCyt Specimens") for testing with the APTIMA Trichomonas…
- Trial name
- NCT01427023
- Testing
- APTIMA Trichomonas vaginalis (ATV) Assay
- Where
- 7 sites in United States
- Volunteers
- 532 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Cervical Cancers, Vulvar Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and…
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions
- Trial name
- NCT00943722
- Testing
- V503
- Volunteers
- 3,074 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Vulvar Cancer
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
The purpose of this study is to evaluate vaccine immunogenicity and how well the body tolerates V504 when given with Gardasil.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00551187
- Testing
- V504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Rheumatoid
Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome
Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.
- Trial name
- NCT02180516
- Testing
- Meloxicam, Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
- Volunteers
- 9,984 people
- Sponsor
- Boehringer Ingelheim
HPV Infections
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9…
- Trial name
- NCT03900572
- Testing
- HPV Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Dystonia
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A
Investigation of the clinical condition in patients with cervical dystonia by Toronto Western Spasmodic Torticollis Scale (TWSTRS)
- Trial name
- NCT02175719
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Eisai Co., Ltd.
Degenerative Disc Disease in Cervical Spine, Stenosis Cervical Spine
PMCF Study Fortilink-SC
This study is setup to be able to gather information on the safety and performance of the Fortilink-SC Ti cage of Paradigm Spine GmbH, up to one year after the surgery.
- Trial name
- NCT07834749
- Testing
- Cervical interbody fusion surgery (standalone)
- Where
- 2 sites in Spain
- Volunteers
- 50 people
- Sponsor
- BAAT Medical Products B.V.
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Cervical Disc Disease, Degenerative Disc Disease
Long-term Assessment of the Safety and Performance of the NuVasive Simplify Disc
A prospective, multicenter post-market clinical follow-up study to evaluate the 10-year long-term safety and effectiveness of the Simplify Disc in subjects who were enrolled in the post approval study (NCT04630626).
- Trial name
- NCT05258435
- Testing
- NuVasive Simplify Cervical Artificial Disc
- Where
- 10 sites in United States
- Volunteers
- 131 people
- Sponsor
- NuVasive
Osteoarthritis, Arthritis
A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup
This is a multi-centre, prospective post marketing surveillance study to assess mid-term performance of the Mpact cup in subjects requiring primary total hip arthroplasty.
- Conditions
- Osteoarthritis, Arthritis, Avascular Necrosis, Fracture of the Femoral Neck or Head
- Trial name
- NCT02196818
- Testing
- Mpact Acetabular Shell
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Medacta International SA
B-cell Acute Lymphoblastic Leukemia, Lymphoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT03638206
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Cervical Dystonia
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia
Investigation of the clinical condition and safety in patients with cervical dystonia
- Trial name
- NCT02175693
- Where
- 2 sites in Japan
- Volunteers
- 1,647 people
- Sponsor
- Eisai Co., Ltd.
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Traumatic Cervical Acute Spinal Cord Injury
Pilot Study of the Neuro-Spinal Scaffold for the Treatment of AIS A Cervical Acute SCI
Pilot Study of Clinical Safety and Feasibility of the Neuro-Spinal ScaffoldTM for the Treatment of Complete (AIS A) Traumatic Acute Spinal Cord Injury at the C5-T1 Neurological Levels The purpose of this study is to support an…
- Trial name
- NCT03105882
- Testing
- Neuro-Spinal Scaffold
- Where
- Canada
- Sponsor
- InVivo Therapeutics